Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $48,090.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 1,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $48.09, for a total value of $48,090.00. Following the completion of the sale, the vice president now owns 33,492 shares of the company's stock, valued at $1,610,630.28. The trade was a 2.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, January 27th, Patrick Lamy sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $57.03, for a total value of $285,150.00.
• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total value of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Stock Down 3.5 %

NASDAQ:AKRO traded down $1.55 on Friday, hitting $42.12. The stock had a trading volume of 947,726 shares, compared to its average volume of 844,922. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a market cap of $2.94 billion, a P/E ratio of -11.23 and a beta of -0.19. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The firm's fifty day simple moving average is $40.49 and its two-hundred day simple moving average is $33.23.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AKRO. GF Fund Management CO. LTD. purchased a new stake in shares of Akero Therapeutics during the 4th quarter worth approximately $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Akero Therapeutics by 18.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company's stock worth $1,988,000 after purchasing an additional 11,035 shares during the last quarter. Woodline Partners LP increased its stake in shares of Akero Therapeutics by 29.9% during the 4th quarter. Woodline Partners LP now owns 379,967 shares of the company's stock worth $10,571,000 after purchasing an additional 87,499 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of Akero Therapeutics by 195.7% during the 4th quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock worth $1,143,000 after purchasing an additional 27,200 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Akero Therapeutics by 43.3% during the 4th quarter. Two Sigma Investments LP now owns 127,320 shares of the company's stock worth $3,542,000 after purchasing an additional 38,500 shares during the last quarter.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of research analyst reports. UBS Group increased their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Morgan Stanley raised their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Finally, Canaccord Genuity Group raised their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics currently has an average rating of "Buy" and an average target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.